Chordate Medical

Sweden
Kista, Stockholm, Sweden, 164 40

Company profile

Chordate Medical company profile

Chordate is a medical technology company that for ten years has developed and patented OZILIA® a new treatment method for chronic migraine and chronic nasal congestion. The global pharmaceutical market for migraine treatments is estimated to amount to approximately SEK 83.7 billion per year within six years. The company offers a CE-marked and patented OZILIA® treatment for chronic migraine and rhinitis. Chordate's treatment has been introduced in selected European and markets in the Middle East.

Business identity

Phone number
+46 8 400 115 86
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0+
Founded
2005-01-01, Year

Headquarters

Postal code
164 40
Country code
SE
Continent
Europe

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
1
Total equity funding
$279,041
Last funding
Post IPO Equity / $279,041 / 2024-11-20
Last equity funding
Post IPO Equity / $279,041
Articles
27
Exited on
2017-03-08

Categories and groups

Founders and investors

No public relation records are available.